Xuanzong Li
Jinan, 250117, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Efficacy and safety of adding induction therapy for unresectable NSCLC receiving cCRT and consolidation immunotherapy: A retrospective study.
Journal: iScience
Published: February 15, 2026
IRF4: A potential prognostic biomarker for immunotherapy in NSCLC.
Journal: International immunopharmacology
Published: June 12, 2024
Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
Journal: Frontiers in immunology
Published: July 09, 2022
XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy.
Journal: Journal of translational medicine
Published: September 21, 2021
Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.
Journal: Frontiers in oncology
Published: April 21, 2021
NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis.
Journal: Clinical lung cancer
Published: February 23, 2021
NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 14, 2020
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 25, 2020
MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 06, 2020
ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 28, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026